Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05736367 · ClinicalTrials.gov registry record · NA

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

A NA study of Breast Cancer, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
NA
Development phase
16
Enrollment target
2
Study locations

NCT05736367 is a NA study of Breast Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 16 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05736367, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
2
Study locations

Study Summary

To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.

Conditions Studied

Interventions

  • DRUG U-13C-glucose

Study Locations (2)

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick
  • RWJBarnabas Health - New Brunswick

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2024-11-15
Est. Completion 2028-06-30
Phase NA

What the Registry Record Tells You About NCT05736367

The ClinicalTrials.gov registry entry for NCT05736367 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which U-13C-glucose is the first listed.

NCT05736367 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT05736367 about?

NCT05736367 is a clinical study titled "Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer". To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.

What is the current status of trial NCT05736367?

This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2024-11-15. Estimated completion is 2028-06-30.

What conditions does trial NCT05736367 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05736367?

The interventions under investigation include: U-13C-glucose (DRUG).

Who is sponsoring clinical trial NCT05736367?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05736367 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.